For over a decade, the American Society of Clinical Oncology’s (ASCO) CancerLinQ platform stood as a noble, yet functionally limited, repository of electronic health record (EHR) data. Originally conceived to aggregate oncology data into a "learning system," the platform largely served as a compliance engine—automating the arduous, manual reporting required for ASCO quality certifications.
However, following its acquisition by ConcertAI in December 2023, CancerLinQ has undergone a radical metamorphosis. No longer just a backend reporting tool, it has been reimagined as a high-velocity, point-of-care oncology intelligence platform. By integrating advanced AI agents and real-world data (RWD) pipelines, ConcertAI is effectively shrinking the gap between cutting-edge clinical research and the bedside reality of patient care.
The Evolution of CancerLinQ: A Chronology of Transformation
The journey of CancerLinQ reflects the broader maturation of the healthcare data industry.
- 2014–2023 (The ASCO Era): CancerLinQ was launched to standardize oncology data collection across various practices. Its primary value proposition was administrative: simplifying the reporting process for physicians seeking to meet rigorous ASCO quality standards. While it built a massive, longitudinal dataset, the platform lacked the "active" clinical utility required for daily decision-making.
- December 2023 (The Acquisition): ConcertAI, a recognized leader in oncology-focused AI and RWD, acquired CancerLinQ from ASCO. The partnership aimed to transition the platform from a static data repository into an active participant in clinical workflows.
- 2024–2026 (The AI Integration): ConcertAI began embedding a chain of AI models to parse unstructured clinical data—such as physician notes, pathology reports, and genomic sequencing—into actionable, structured insights.
- Present Day (The Agentic Era): The platform now functions as a "lane assist" for oncologists, providing real-time trial matching, care-gap identification, and diagnostic summarization.
Closing the Gap: From Data Silos to Clinical Action
The fundamental challenge in modern oncology is the speed at which science moves compared to the speed at which clinical practice adapts. Shaalan Beg, MD, ConcertAI’s Chief Medical Officer for Oncology, notes that in diseases like metastatic pancreatic cancer, the difference between standard-of-care and life-extending innovation is often found only within the context of a clinical trial.
“If you’re a pancreatic cancer patient right now and you want the best standard of care, the only way you’re going to get it is through clinical trials,” Dr. Beg explains. Recent data, such as findings showing a new agent nearly doubling median survival in previously treated patients—from six months to 12 months—underscores the urgency of connecting patients to trials immediately upon diagnosis or progression.
ConcertAI bridges this gap by acting as a platform-agnostic layer that sits atop any EHR vendor. By ingesting and refreshing clinical datasets weekly, the platform ensures that the most recent laboratory reports, genomic findings, and clinical notes are available to inform treatment decisions, regardless of the hospital’s specific software infrastructure.
Supporting Data: The Surge in AI Adoption
The transition toward AI-augmented clinical practice is not merely a technical trend; it is a clinical necessity driven by the increasing complexity of oncology. According to the American Medical Association (AMA), physician engagement with AI has skyrocketed:
- Usage: In 2023, only 38% of physicians reported incorporating AI into their clinical practice. By 2026, that figure climbed to 72%.
- Awareness: Physician awareness of AI capabilities jumped from 66% in 2025 to 81% in 2026.
- Utility: Nearly 40% of physicians now prioritize AI for summarization and research, marking a 26-point increase since 2024.
This data suggests that the "human-in-the-loop" model—where AI provides the intelligence and the clinician provides the judgment—has moved from a theoretical ideal to a standard operational requirement.
Official Perspectives: The "Lane Assist" Analogy
Eron Kelly, CEO of ConcertAI, emphasizes that the goal is not to replace the physician, but to enhance their decision-making capacity. "We use a chain of AI models and agents to parse all that information, understand really challenging concepts like progression, or timelines within a diagnosis journey, and summarize that into a structured data model," Kelly states.
Dr. Beg adds a compelling analogy, describing the current iteration of the platform as "lane assist" for oncology. "It’s about keeping the car in its lane and giving nudges along the way," he says. These nudges might take the form of identifying a missing molecular test for a colon cancer patient or flagging a trial for which a patient is newly eligible.
Crucially, these tools are built to address the "capacity crisis" in modern oncology. As medicine becomes more personalized, the care of a single patient now requires a massive multidisciplinary team—geneticists, dietitians, nurse practitioners, and physical therapists. Since few institutions are fully staffed to handle this complexity, AI serves as an essential efficiency layer, allowing oncologists to focus on high-value patient interactions rather than data extraction.
Technical Trust: How Agents Ensure Accuracy
A common criticism of AI in healthcare is the "black box" problem. ConcertAI addresses this through a layered validation system. Rather than relying on a single model, the platform uses a chain of agents that cross-check one another.
- Abstraction Accuracy: One agent evaluates whether the model correctly interpreted the raw data in the chart.
- Clinical Coherence: A second agent ensures that the sequence of events makes medical sense. For example, it might flag a treatment protocol that would not typically follow a specific radiation therapy.
This verification layer ensures that the system’s output remains trustworthy. When the AI surfaces a potential trial match or a shift in diagnosis, it provides a direct link back to the source record, ensuring that the physician is always looking at the original clinical evidence.
Implications: The Shift Toward "Ground Shots"
Perhaps the most profound implication of this technological shift is the philosophical change in how we view cancer breakthroughs. For decades, the focus has been on "Moonshots"—the quest for a single, sweeping cure. While revolutionary therapies like CAR-T and checkpoint inhibitors are essential, Dr. Beg argues for a shift toward what he calls "ground shots."
"I think we should focus on ground shots first, disseminating the treatments we already know work to the people who need them right now," Beg says.
By leveraging the platform’s ability to identify patients who were previously misclassified—such as patients who might have been labeled "HER2-negative" under older criteria but who qualify for modern antibody-drug conjugates—ConcertAI is maximizing the utility of existing scientific progress.
Conclusion: Empowering the Future of Oncology
The integration of CancerLinQ into ConcertAI’s ecosystem represents a maturation of the oncology field. By moving from simple compliance reporting to an agentic AI framework, the platform is effectively reducing the cognitive load on oncologists while simultaneously ensuring that no patient is left behind due to administrative oversight or data fragmentation.
As the industry continues to refine these tools, the focus remains clear: providing clinicians with the precision, time, and data necessary to deliver the right treatment at the right time. In the complex, fast-moving landscape of cancer care, ConcertAI is proving that the most important technological advancement may not be a new drug, but a better way to ensure the drugs we already have reach the patients who need them most.
About the Author
